ASX:ADR

Adherium Stock Forecast, Price & News

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

Volume38,277 shs

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Receive ADR News and Ratings via Email

Sign-up to receive the latest news and ratings for Adherium and its competitors with MarketBeat's FREE daily newsletter.

About Adherium

Adherium Limited develops, manufactures, and supplies digital health technologies that address sub-optimal medication use in chronic diseases in New Zealand, Australia, Europe, North America, and Asia. It offers Hailie, an asthma and COPD medication adherence solution for patients with chronic respiratory diseases. The company also provides a range of smart device sensors for respiratory medications, such as Bluetooth enabled Hailie sensors wrap around a patient's existing inhalers and automatically send usage data to their smartphone; and Hailie app that enables patients, caregivers, and healthcare professionals to track medication adherence, set daily reminders, and discover insights into their medication usage. It offers its digital health solutions to patients, pharmaceutical companies, healthcare providers, and contract research organizations. The company has a collaboration with HGE Health in COPD. The company was founded in 2001 and is headquartered in Auckland, New Zealand.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Stock Exchange: ASX
Industry: Medical Devices
Sub-Industry: N/A
Sector: Medical
Current Symbol: ASX:ADR
Previous Symbol
CUSIP: N/A
CIK: N/A
Web: www.adherium.com
Phone: 64 9 307 2771
Employees: N/A
Year Founded: N/A

Sales & Book Value

Annual Sales: $401,000.00
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 10.00
Book Value: A$0.01 per share
Price / Book: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Net Income: N/A
Net Margins: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.63
Quick Ratio: 5.24

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: N/A
Market Cap: N/A
Next Earnings Date: N/A
Optionable: Not Optionable

MarketRank^™

Overall MarketRank^™

1.00 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Adherium.

5.0 Community Rank

Outperform Votes
Adherium has received 15 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Adherium has received 5 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Adherium has received 75.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Adherium and other stocks. Vote “Outperform” if you believe ADR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ADR will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Adherium does not currently pay a dividend.
Dividend Growth
Adherium does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Adherium insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Adherium (ASX:ADR) Frequently Asked Questions

What stocks does MarketBeat like better than Adherium?: Wall Street analysts have given Adherium a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Adherium wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.
Who are Adherium's key executives?: Adherium's management team includes the following people:
Ms. Anne M. Bell, Chief Financial Officer
Mr. Michael Motion, Consultant
Mr. Rob Turnbull B.Com., C.A., B.Com, CA., GM & Joint Company Sec. (Age 54, Pay $293.14k)
Mr. Mark Andrew Licciardo B Bus (Acc), FCIS, GAICD, GradDip CSP, FGIA, Joint Company Sec. (Age 57, Pay $7.08k)
Mr. Rick Legleiter B.S., M.B.A., Chief Exec. Officer (Age 62)
Mr. Geoff Feakes, Chief Technology Officer
Mr. Chris Mander, Head of Regulatory & Quality
Ms. Maggie Scott, Head of Clinical Operations
Dr. John Douglas Wilson, Exec. Medical Director (Age 84)
Who are some of Adherium's key competitors?: Some companies that are related to Adherium include 4DMedical (4DX), ADM Tronics Unlimited (ADMT), Allegra Orthopaedics (AMT), Analytica (ALT), AnteoTech (ADO), Anteris Technologies (AVR), Asensus Surgical (ASXC), Atomo Diagnostics (AT1), AVITA Medical (AVH), Azure Healthcare Limited (AZV.AX) (AZV), Cannabix Technologies (BLO), CleanSpace (CSX), Cochlear (COH), Cochlear (CHEOY) and Cochlear (CHEOF).
View all of ADR's competitors.
What is Adherium's stock symbol?: Adherium trades on the ASX under the ticker symbol "ADR."
How much money does Adherium make?: Adherium has a market capitalization of $0.00 and generates $401,000.00 in revenue each year.
What is Adherium's official website?: The official website for Adherium is www.adherium.com.
How can I contact Adherium?: The company can be reached via phone at 64 9 307 2771.

This page was last updated on 9/27/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms

Your Ultimate Investing Toolkit

Just $1.00 for your first month.